ArticlePloS one2026
Single-cell multiomics data analysis of potential receptors and therapeutic drugs for epilepsy patients comorbid with depression.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression frequently cooccurs with epilepsy (EP) and has become a focus of clinical management, but effective pharmacological interventions remain limited. In this study, single-cell RNA sequencing (scRNA-seq) data were analyzed to identify changes in oligodendrocyte precursor cells (OPCs) in EP and major depressive disorder (MDD) patients, and intercellular communication and trajectory analyses were performed. Key therapeutic targets and pathways were identified via differentially expressed genes (DEGs), protein-protein interaction (PPI) networks, and gene ontology (GO) enrichment. A connectivity map (CMap) was generated to identify optimal drugs. Molecular dynamics simulation (MDs) and cell thermal stability migration assay (CETSA) were conducted to evaluate protein-drug interactions. The results revealed significant changes in gene expression in OPCs, with neuroligin3 (NLGN3)-neurexin (NRXN) signaling being the main pathway involved. Three hub genes correlated with NLGN3 were enriched in oxidative phosphorylation and mTORC1 signaling. Ziprasidone could effectively treat EP with MDD by strongly binding to NLGN3, forming two hydrogen bonds with a binding energy of -7.5 kcal/mol. This stable interaction was further confirmed by MDs and CETSA experiments. In conclusion, the NLGN3 protein interacts with ziprasidone to form stable complexes, which may activate the NLGN3-NRXN signaling pathway in OPCs and enhance synaptic remodeling by reducing neuroinflammatory responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.